Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — and unlike most peptides in this database, it actually has FDA approval (for HIV-associated lipodystrophy/belly fat). This gives it something rare in the peptide world: pharmaceutical-grade manufacturing, clinical trial data, and a known safety profile.

What makes Tesamorelin interesting beyond its approved indication is what the clinical data shows: significant reduction in visceral fat (the dangerous fat around organs), improvements in cognitive function (multiple trials in healthy older adults showing memory enhancement), and favourable effects on liver fat. It works by stimulating your own pituitary to produce more growth hormone — preserving the natural pulsatile release pattern rather than flooding your system with exogenous GH.

The biohacking community uses Tesamorelin as a 'cleaner' alternative to direct growth hormone injection. Because it works through your own pituitary, there is feedback regulation — you cannot easily overshoot into GH excess the way you can with direct GH administration. The cognitive data is particularly exciting: this is one of few compounds showing genuine memory improvement in healthy older adults.

How Does It Work?

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating production and pulsatile release of growth hormone. Key distinctions from direct GH:

1. Preserves pulsatility — GH is released in natural pulses, not continuous elevation. 2. Feedback intact — if GH/IGF-1 gets too high, somatostatin suppresses further release. 3. Stimulates entire GH axis — including local tissue GH production.

Downstream effects of increased GH: lipolysis (fat breakdown), especially visceral fat; hepatic IGF-1 production; nitrogen retention; improved sleep quality. Cognitive effects may be mediated by IGF-1's neurotrophic actions or direct GH effects on hippocampal function.

What Does The Research Say?

Lipodystrophy (FDA-approved): Multiple Phase 3 trials showing significant visceral fat reduction in HIV patients. Trunk fat decreased 15-18% vs placebo.

Cognition: Multiple trials in healthy older adults and MCI patients showing improved verbal memory, executive function, and reduced Alzheimer's biomarkers (P-tau). This cognitive data is remarkable for a non-cognitive-targeted drug.

Liver: Reduces hepatic fat in NAFLD — potential therapeutic application being studied.

Body composition in non-HIV: Off-label data shows visceral fat reduction in general obesity/metabolic syndrome.

Reported Dosages

FDA-approved dose: 2mg subcutaneous daily (for lipodystrophy).

Off-label/biohacking: 1-2mg daily, often cycled (weekdays on, weekends off) or 5 days on/2 off.

Best administered before bed or morning on empty stomach (to align with natural GH pulses).

Available as pharmaceutical (Egrifta) with prescription, or from peptide suppliers.

DISCLAIMER: Off-label use requires medical supervision. Monitor IGF-1 levels to ensure you stay within physiological range. Do not use if you have active malignancy.

Side Effects & Risks

Injection site reactions (common), joint pain/arthralgia, peripheral oedema (fluid retention), paresthesia (tingling), headache. These are typical GH-axis side effects and are dose-dependent.

More serious: can worsen glucose tolerance (GH is counter-regulatory to insulin). Monitor blood glucose. Contraindicated in active malignancy (GH/IGF-1 can promote tumour growth). Discontinue if hypersensitivity reaction occurs.

Legal Status by Country